Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Non-Current Assets (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Non-Current Assets data on record, last reported at $1.0 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 25.11% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.0 million, down 25.11%, while the annual FY2024 figure was $1.3 million, 7.78% down from the prior year.
  • Non-Current Assets reached $1.0 million in Q3 2025 per CRVS's latest filing, down from $13.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $13.9 million in Q1 2025 and bottomed at $1.0 million in Q3 2025.
  • Average Non-Current Assets over 4 years is $3.1 million, with a median of $1.4 million recorded in 2023.
  • The widest YoY moves for Non-Current Assets: up 1047.73% in 2025, down 25.11% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $1.7 million in 2022, then fell by 13.62% to $1.4 million in 2023, then fell by 7.78% to $1.3 million in 2024, then decreased by 23.63% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $1.0 million in Q3 2025, $13.7 million in Q2 2025, and $13.9 million in Q1 2025.